Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. 1996

D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
Infectious Diseases Associates of Kansas City, Missouri, USA.

We assessed the efficacy of oral fluconazole (200-800 mg daily) in the treatment of non-life-threatening acute pulmonary histoplasmosis, chronic pulmonary histoplasmosis, or disseminated histoplasmosis in patients without human immunodeficiency virus infection. Of 27 evaluable patients, two had progressive acute pulmonary histoplasmosis, 11 had chronic pulmonary histoplasmosis, and 14 had disseminated histoplasmosis. Median durations of treatment in each of the three groups were 6 months, 7 months, and 11 months, respectively. Nineteen patients were treated with 400 mg of fluconazole daily (two of these patients received 800 mg daily for a portion of their treatment courses), seven were treated with 200 mg daily, and one was treated with 800 mg daily. Treatment was successful in 17 (63%) of 27 cases. Both of the patients with acute pulmonary infection responded to therapy, as did five (46%) of 11 patients with chronic pulmonary infection and 10 (71%) of 14 patients with disseminated infection. No substantial toxicity was observed. We conclude that fluconazole therapy for histoplasmosis is only moderately effective and should be reserved for patients who cannot take itraconazole.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006660 Histoplasmosis Infection resulting from exposure to the fungus HISTOPLASMA. African Histoplasmosis,Disseminated Histoplasmosis,Histoplasma duboisii Infection,Pulmonary Histoplasmosis,Histoplasma Infection,Histoplasma capsulatum Infection,Histoplasma Infections,Histoplasma capsulatum Infections,Histoplasma duboisii Infections,Histoplasmosis, African,Histoplasmosis, Disseminated,Histoplasmosis, Pulmonary,Infection, Histoplasma,Infection, Histoplasma capsulatum,Infection, Histoplasma duboisii
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015337 Multicenter Studies as Topic Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. Multicenter Trials,Multicentre Studies as Topic,Multicentre Trials,Multicenter Trial,Multicentre Trial,Trial, Multicenter,Trial, Multicentre,Trials, Multicenter,Trials, Multicentre
D015725 Fluconazole Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS. Apo-Fluconazole,Béagyne,Diflucan,Fluc Hexal,FlucoLich,Flucobeta,Fluconazol AL,Fluconazol AbZ,Fluconazol Stada,Fluconazol von ct,Fluconazol-Isis,Fluconazol-ratiopharm,Flunazul,Fungata,Lavisa,Loitin,Neofomiral,Oxifungol,Solacap,Triflucan,UK-49858,Zonal,Apo Fluconazole,Fluconazol Isis,Fluconazol ratiopharm,UK 49858,UK49858
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
February 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
August 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
February 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
December 1985, Annals of internal medicine,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
March 1999, The New England journal of medicine,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
June 1995, The Journal of infectious diseases,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
July 1997, The New England journal of medicine,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
October 1982, The Journal of infectious diseases,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
July 1993, Annals of internal medicine,
D S McKinsey, and C A Kauffman, and P G Pappas, and G A Cloud, and W M Girard, and P K Sharkey, and R J Hamill, and C J Thomas, and W E Dismukes
November 1992, The American journal of medicine,
Copied contents to your clipboard!